Articolul precedent |
Articolul urmator |
513 1 |
Ultima descărcare din IBN: 2024-02-28 11:54 |
SM ISO690:2012 MUNTEANU (IVANOV), Mihaela, GALESCU, Andrei, GHICAVÎI, Vitalie, CEBAN, Emil. The role of botulinum toxin type a in treatment of overactive bladder (clinical case). In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 255. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 255-255 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Botulinum toxin type A (BTX-A) is effective in treatment of overactive bladder (OAB) in women with ineffective anticholinergic treatment, inhibiting detrusor muscle contraction by temporary paralysis, improving bladder storage and urination function. Objective of the study. Evaluation of efficacy and safety of intravesical administration by injection of botulinum toxin type A in women with idiopatic overactive bladder. Material and Methods. The OAB clinical diagnosis was established based on the bladder diary, the ICIQ-OAB, ICIQ-UI, OABSS, HRQL questionnaires, and based on the urodynamic tests. BTX-A (100 IU) was diluted with 10ml saline sol. 0.9% and subsequently applied 20 injections, 0.5ml each with a depth of 3mm intradetrusor, superior of the bladder trigone, using a 8Ch needle. Results. The questionnaires established the presence of severe clinical manifestations and severe impairment on quality of life(HRQL 38.4) .The bladder post void residual volume=71ml. Urodynamic tests confirmed the presence of OAB and DO: maximum bladder capacity 118ml; first sensation 34ml, first desire 63ml; strong desire to urinate 102ml; number of detrusor contractions; detrusor contractility index(IC=288). First urination was after 2-3h of BTX-A injection, and after 4 days was established the disappearance of all previously urinary symptoms. The period between post-injection effect with BTX-A and the recurrence of OAB clinical manifestations~12 months. Conclusion. Benefit of BTX-A intravesical therapy in women with OAB, refractory to anticholinergic treatment is a cost-effective, safety alternative treatment, improving the patient's quality of life, due to the prolonged period between injections. |
||||||
Cuvinte-cheie Overactive bladder, detrusor, Botulinum toxin type A, urodynamics, vezica urinară hiperactivă, detrusor, toxina botulinică, urodinamică |
||||||
|